This trial will study the effects of ofatumumab in people with RRMS who are in the early stages of the disease. The study will use clinical and MRI outcomes to track changes in the disease, as well as digital devices, biomarkers, and non-conventional MRI. The results of the ofatumumab group will be compared to a group of healthy people to see if there are any similarities between the two groups after treatment.
1 Primary · 12 Secondary · Reporting Duration: Month 6 to Month 18 and 30
168 Total Participants · 2 Treatment Groups
Primary Treatment: Ofatumumab · No Placebo Group · Phase 4
Age 18 - 35 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: